Clinical trials: Atorvastatin
Healthy Volunteer
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and atorvastatin from prototype fixed dose combination formulations in healthy volunteers.
- Trial name
- NCT01363999
- Testing
- atorvastatin, dalcetrapib
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hypercholesterolaemia
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
To evaluate the effect of atorvastatin 80 mg, versus placebo, given for 12 months on carotid intima-media thickness in postmenopausal women with moderate hypercholesterolemia.
- Trial name
- NCT00163163
- Testing
- Echographic measurements, Blood samples
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 400 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Atherosclerotic Cardiovascular Disease
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this…
- Trial name
- STaRT (NCT06858332)
- Testing
- Atorvastatin, Simvastatin, Rozuvastatin
- Where
- 20 sites in Russia
- Volunteers
- 2,382 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
The objective of this study is to evaluate the effects of adding Tricor 145 mg to once daily atorvastatin 20 mg on CHD lipid laboratory parameters.
- Trial name
- NCT00195793
- Testing
- fenofibrate, ezetimibe, atorvastatin
- Volunteers
- 174 people
- Sponsor
- Abbott
Hyperlipidemia
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
The intent of this study is to demonstrate that single doses of the Final Market Image (FMI) ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are bioequivalent to the same doses of ezetimibe…
- Trial name
- NCT01236430
- Testing
- Ezetimibe, Ezetimibe/atorvastatin 10mg/10mg FDC, Atorvastatin 10mg
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Obesity
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and
- Trial name
- NCT07362030
- Testing
- RAY1225, atorvastatin calcium tablet, Metformin Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Drug-Interactions
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT04764851
- Testing
- ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Hypercholesterolemia
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
The purpose of this study is to compare the efficacy and safety of rosuvastatin with simvastatin and atorvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia
- Trial name
- SOLAR (NCT00654173)
- Testing
- Rosuvastatin, Simvastatin, Atorvastatin
- Volunteers
- 4,444 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.
- Trial name
- NCT00092716
- Testing
- MK0653, ezetimibe / Duration of Treatment: 28 weeks, Comparator: atorvastatin / Duration of Treatment: 28 weeks
- Volunteers
- 655 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Atherosclerotic Disease
Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)
A 6-week treatment study to compare the reduction in cholesterol of two drugs MK0653A+Simvastatin for high cholesterol, in patients with hypercholesterolemia and atherosclerotic or coronary vascular disease.
- Conditions
- Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease
- Trial name
- NCT00090168
- Testing
- MK0653A , ezetimibe (+) simvastatin, Comparator: atorvastatin, Duration of Treatment: 6 weeks
- Volunteers
- 435 people
- Sponsor
- Organon and Co
Healthy
CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
A randomized open-label, multiple dose, three-treatment, three-period, six-sequence, crossover study to investigate the pharmacokinetic drug interaction between Atorvastatin and Ezetimibe after oral administration in healthy…
- Trial name
- NCT02288338
- Testing
- 1 (Lipitor®), 1 (Ezetrol®), 1 (Lipitor®, Ezetrol®)
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen.
- Trial name
- NCT01926782
- Testing
- Alirocumab, Statin
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 803 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolaemia
PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment
- Trial name
- NCT00329173
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein…
- Trial name
- BERSON (NCT02662569)
- Testing
- Evolocumab, Atorvastatin
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 986 people
- Sponsor
- Amgen
Dyslipidemias
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or…
- Trial name
- NCT02977065
- Testing
- Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemias, Coronary Heart Disease
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal…
- Conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Trial name
- NCT00639158
- Testing
- ABT-335, atorvastatin, ezetimibe
- Where
- 118 sites in United States
- Volunteers
- 543 people
- Sponsor
- Abbott
Hyperlipidemia (E.G., Hypercholesterolemia)
Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population.
- Trial name
- NCT06789432
- Testing
- Atorvastatin 10 mg and ezetimibe 10 mg, Atorvastatin 20 mg
- Where
- Bangladesh
- Sponsor
- Dr. Md. Alimur Reza
Hypertension With Hyperlipidemia
Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers
study to evaluate drug-drug interaction following oral administration of telmisartan/amlodipine and atorvastatin in healthy adult volunteers
- Trial name
- NCT03461081
- Testing
- telmisartan/amlodipine and atorvastatin
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hypertension, Hyperlipidemia
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.
- Trial name
- NCT01442987
- Testing
- Irbesartan/Atorvastatin A, Irbesartan, Atorvastatin A
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Cancer, Overall Survival
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree…
- Trial name
- METRICS (NCT02201381)
- Testing
- Metabolic treatment
- Where
- United Kingdom
- Sponsor
- Health Clinics Limited